<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of an Exclusive Patent License: N-butyldeoxynojirimycin To Treat Smith-Lemli Opitz Syndrome (SLOS) and Diseases That Exhibit a Similar NPC-Like Cellular Phenotype</h1>
    <p class="timestamp">Published: 2021-04-09 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Institute of Child Health and Human Development, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and foreign Patents and Patent Applications listed in the Supplementary Information section of this notice to SubRed Pty Ltd located in Australia, registered in Victoria.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2021-07316</p>
    <p><strong>Publication Date:</strong> 2021-04-09</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2021/04/09/2021-07316/prospective-grant-of-an-exclusive-patent-license-n-butyldeoxynojirimycin-to-treat-smith-lemli-opitz">https://www.federalregister.gov/documents/2021/04/09/2021-07316/prospective-grant-of-an-exclusive-patent-license-n-butyldeoxynojirimycin-to-treat-smith-lemli-opitz</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2021-07316</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
